The ZOLADEX® (goserelin) monthly (3.6mg) implant will be unavailable on the Pharmaceutical Benefits Scheme (PBS) in Australia from 1 November 2026.
We understand that maintaining continuity of care is essential. For patients without suitable treatment pathways, AstraZeneca is providing Zoladex monthly (3.6mg) implant at no cost in Australia from 1 November 2026. Standard pharmacy dispensing fees may still apply.
Health care professionals have been notified of the change in process for prescribing the Zoladex monthly (3.6mg) implant for patients without suitable treatment pathways. This includes patients who are currently prescribed and patients who may need to be prescribed the implant as a treatment option after 1 November 2026.
The decision to discontinue the Zoladex monthly (3.6mg) implant from Australia’s Pharmaceutical Benefits Scheme reflects the way the PBS currently works, which means that the price offered is too low, making it unsustainable to supply the medicine on the PBS.
Changes to Zoladex (goserelin) availability in other countries will not impact Australian patients.
AstraZeneca follows the rules set by Medicines Australia and the Therapeutic Goods Advertising Code which restricts the information we can provide about our medicines to the general public on our website. Contact our Medical Information team at 1800 805 342 or MedInfo.Australia@astrazeneca.com if you have further questions.
Please click here to view consumer medicine information. PBS Information: Refer to the current PBS Schedule.
ZOLADEX® (3.6mg) Therapeutic Indications:
- Palliative treatment of metastatic or locally advanced prostate cancer, where suitable, for hormonal manipulation.
- Adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation.
- Treatment of advanced breast cancer in premenopausal women suitable for hormonal manipulation.
- Adjuvant therapy in early breast cancer, in pre- and perimenopausal women suitable for hormonal manipulation.
- Management of visually proven endometriosis to reduce symptoms including pain and the size and number of endometrial lesions.
- Management of fibroids, to shrinks lesions and reduce symptoms, including pain. ZOLADEX® also increases the haemoglobin concentration and haematocrit in women with anaemia attributable to menorrhagia. It is used as an adjunct to surgery to facilitate the operative technique and reduce operative blood loss.
- Used as an endometrial thinning agent prior to endometrial ablation.
- In assisted reproduction, for pituitary down regulation in preparation for controlled ovarian superstimulation.
Safety:
All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical treatment if you get some of the common side effects, such as changes in blood pressure, hot flushes, chills, headache, skin rashes, sweating, tingling or numbness, breast tenderness, breast enlargement, vaginal dryness, altered mood, erectile dysfunction, pain, and injection site reactions. Ask your doctor or pharmacist to answer any questions you may have.
ZOLADEX® belongs to the class of gonadotropin-releasing hormone agonists and is a registered trademark of AstraZeneca. AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. www.astrazeneca.com.au. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone 1800 805 342 or via https://contactazmedical.astrazeneca.com | AU-25768 July 2026